Market Overview:
The global bystolic (nebivolol) market is expected to register a CAGR of 5.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of hypertension and heart failure across the globe. Bystolic (nebivolol) is a beta blocker used in the treatment of hypertension and heart failure. It is available in two dosages, 5 mg and 10 mg tablets. The drug reduces blood pressure by blocking beta receptors located on arterial smooth muscle cells, which leads to a decrease in cardiac output and systemic vascular resistance. It also decreases heart rate by blocking beta-1 receptors located on cardiac pacemaker cells, leading to an increase in atrial filling time and decreased ventricular response rate.
 ( CAS 99200-09-6) Industry Outlook.svg)
Product Definition:
A beta blocker prescribed to treat high blood pressure and heart failure. It works by blocking the effects of adrenaline on the heart.
5 mg:
5 mg is used for the treatment of hypertension and coronary artery disease. It also helps in reducing the risk of stroke, myocardial infarction, and cardiovascular death. Increasing incidences of these diseases due to changing lifestyle are expected to drive market growth over the forecast period.
10 mg:
10 mg is used to treat hypertension and congestive heart failure. It works by relaxing the blood vessels, which reduces the pressure in the arteries. Increasing awareness about hypertension and it's effects on a person's health has led to an increase in treatment rates over recent years.
Application Insights:
On the basis of application, the global bystolic (nebivolol) market is segmented into hypertension, heart failure and others. Hypertension was estimated as the largest segment in 2017 owing to high prevalence of high blood pressure among various age groups. According to a study published in The Lancet, around 1 billion people have hypertension worldwide. In addition, another study states that every year around 70 million people are newly diagnosed with hypertension and it will become a major health problem by 2030 if steps are not taken against it now.
The use of bystolic for treating patients suffering from heart failure is relatively new and requires more clinical trials before its full acceptance as an effective treatment option for this condition.
Regional Analysis:
North America dominated the global bystolic market with a share of over 50.0% in 2017. This is attributed to the local presence of key manufacturers such as Cipla Inc., and Volkart Group, which are responsible for increasing product availability in this region. Moreover, new product launches coupled with high consumer awareness levels regarding cardiovascular diseases are expected to further fuel the regional growth during the forecast period.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising healthcare expenditure and growing patient awareness about newly launched products such as bystolic 5 mg & 10 mg tablets (immediate release formulation). Furthermore, an increase in target population base due to rapid urbanization and aging demographics will drive demand for Nebivol drug products in Asia Pacific countries like Japan, China & India during the forecast period from 2018-2030 (USD Million).
Growth Factors:
- Increasing prevalence of hypertension and other cardiac disorders
- Rising geriatric population
- Growing awareness about the benefits of Nebivolol therapy
- Technological advancements in the field of Nebivolol drug delivery systems
- Availability of generic versions of Nebivolol
Scope Of The Report
Report Attributes
Report Details
Report Title
Bystolic (Nebivolol) ( CAS 99200-09-6) Market Research Report
By Type
5 mg, 10 mg
By Application
Hypertension, Heart Failure, Others
By Companies
Allergan plc (AbbVie Inc.), Mylan Laboratories, Actavis Generics (Teva), Zydus Healthcare Ltd, Eris lifesciences, Cipla ltd, Lupin ltd, Abbott, Cadila Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
172
Number of Tables & Figures
121
Customization Available
Yes, the report can be customized as per your need.
Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market Report Segments:
The global Bystolic (Nebivolol) ( CAS 99200-09-6) market is segmented on the basis of:
Types
5 mg, 10 mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hypertension, Heart Failure, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan plc (AbbVie Inc.)
- Mylan Laboratories
- Actavis Generics (Teva)
- Zydus Healthcare Ltd
- Eris lifesciences
- Cipla ltd
- Lupin ltd
- Abbott
- Cadila Pharmaceuticals
 ( CAS 99200-09-6) Market Overview.svg)
Highlights of The Bystolic (Nebivolol) ( CAS 99200-09-6) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5 mg
- 10 mg
- By Application:
- Hypertension
- Heart Failure
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bystolic (Nebivolol) ( CAS 99200-09-6) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 ( CAS 99200-09-6) Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bystolic is a beta blocker. It works by blocking the action of adrenaline and other hormones that can cause heart problems. Bystolic is used to treat high blood pressure, heart failure, or angina (chest pain).
Some of the key players operating in the bystolic (nebivolol) ( cas 99200-09-6) market are Allergan plc (AbbVie Inc.), Mylan Laboratories, Actavis Generics (Teva), Zydus Healthcare Ltd, Eris lifesciences, Cipla ltd, Lupin ltd, Abbott, Cadila Pharmaceuticals.
The bystolic (nebivolol) ( cas 99200-09-6) market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bystolic (Nebivolol) ( CAS 99200-09-6) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bystolic (Nebivolol) ( CAS 99200-09-6) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bystolic (Nebivolol) ( CAS 99200-09-6) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bystolic (Nebivolol) ( CAS 99200-09-6) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market Size & Forecast, 2020-2028
4.5.1 Bystolic (Nebivolol) ( CAS 99200-09-6) Market Size and Y-o-Y Growth
4.5.2 Bystolic (Nebivolol) ( CAS 99200-09-6) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 5 mg
5.2.2 10 mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hypertension
6.2.2 Heart Failure
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bystolic (Nebivolol) ( CAS 99200-09-6) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 5 mg
9.6.2 10 mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hypertension
9.10.2 Heart Failure
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 5 mg
10.6.2 10 mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hypertension
10.10.2 Heart Failure
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 5 mg
11.6.2 10 mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hypertension
11.10.2 Heart Failure
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 5 mg
12.6.2 10 mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hypertension
12.10.2 Heart Failure
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 5 mg
13.6.2 10 mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hypertension
13.10.2 Heart Failure
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bystolic (Nebivolol) ( CAS 99200-09-6) Market: Competitive Dashboard
14.2 Global Bystolic (Nebivolol) ( CAS 99200-09-6) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan plc (AbbVie Inc.)
14.3.2 Mylan Laboratories
14.3.3 Actavis Generics (Teva)
14.3.4 Zydus Healthcare Ltd
14.3.5 Eris lifesciences
14.3.6 Cipla ltd
14.3.7 Lupin ltd
14.3.8 Abbott
14.3.9 Cadila Pharmaceuticals
